
Deborah J. Wexler MD, MSc
Associate Professor of Medicine, Harvard Medical School; Associate Clinical Chief, Diabetes Unit, and Clinical Director, Massachusetts General Hospital Diabetes Center, Boston, MassachusettsDr. Deborah J. Wexler’s research focuses on clinical effectiveness in type 2 diabetes. In addition, she is on the Editorial Board of Diabetes Care, and is a reviewer for multiple journals.
Dr. Wexler was a co-author of the ADA-EASD Consensus Report on Management of Type 2 Diabetes, 2018.https://care.diabetesjournals.org/content/early/2018/09/27/dci18-0033
Disclosures
Dr. Wexler reports serving on Data Monitoring Committees for trials of oral semaglutide sponsored by Novo Nordisk.
Recent Contributions to PracticeUpdate:
- ADA 2022: Recommendations From Dr. Deborah Wexler
- 2021 Top Story in Diabetes: Empagliflozin for Heart Failure With Preserved Ejection Fraction
- Hemoglobin A1c Reduction and CV Risk Improvement: Correlation, Causation and Clinical Recommendations
- Rationale and Clinical Utility of Sulfonylureas in Contemporary Practice
- Comparative Effectiveness of a DPP-4 Inhibitor, a Sulfonylurea, a GLP-1 Agonist, and Basal Insulin: Data From the GRADE Trial
- ADA 2021: Recommendations From Dr. Deborah Wexler
- 2020 Top Stories in Diabetes: The DAPA-CKD Trial
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
- 2019 Top Stories in Diabetes: The CREDENCE Trial
- Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes